{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:26:34Z","timestamp":1773944794819,"version":"3.50.1"},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.18632\/oncotarget.12247","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T18:08:26Z","timestamp":1474913306000},"page":"71536-71547","source":"Crossref","is-referenced-by-count":10,"title":["A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer"],"prefix":"10.18632","volume":"7","author":[{"given":"Lorenz","family":"Jahn","sequence":"first","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk M.","family":"van der Steen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pleun","family":"Hombrink","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"},{"name":"Department of Hematopoiesis, Sanquin Research, 1006 AD Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel G.D.","family":"Kester","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein P.","family":"Schoonakker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00eblle","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"van Veelen","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam H.M.","family":"Heemskerk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"June","year":"2013","journal-title":"N Engl J Med"},{"key":"2","first-page":"95ra73","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"June","year":"2011","journal-title":"Sci Transl Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"June","year":"2011","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Rosenberg","year":"2010","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"Lister","year":"1998","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Welker","year":"2005","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Fisher","year":"2001","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Devillier","year":"2012","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","article-title":"Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma","volume":"38","author":"Spencer","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.anai.2012.09.021","article-title":"Prolonged hypogamma- globulinemia after adjuvant rituximab for Hodgkin's lymphoma presenting with refractory urticaria","volume":"109","author":"McClenathan","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable Remissions in Children with Relapsed\/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)","volume":"126","author":"Wood","year":"2015","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Donato","year":"2008","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1016\/S0021-9258(18)53139-2","article-title":"CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin","volume":"268","author":"Stamenkovic","year":"1993","journal-title":"J Biol Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"44315","DOI":"10.1074\/jbc.M105446200","article-title":"CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1","volume":"276","author":"Clark","year":"2001","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Orentas","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Adamson","year":"2008","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Sierra","year":"2010","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Fayad","year":"2012","journal-title":"Lancet Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"de Vries","year":"2006","journal-title":"Science"},{"key":"21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Restifo","year":"2011","journal-title":"J Clin Oncol"},{"key":"22","article-title":"The human leukocyte antigen-presented ligandome of B lymphocytes","author":"Veelen","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T-cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Lund","year":"2003","journal-title":"Protein Sci"},{"key":"24","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3. 0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11","volume":"36","author":"Nielsen","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"Heemskerk","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"26","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1182\/blood-2011-05-354787","article-title":"Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific","volume":"118","author":"Heemskerk","year":"2011","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"van Veelen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1182\/blood-2003-11-3903","article-title":"Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen","volume":"103","author":"Stauss","year":"2004","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/leu.2010.186","article-title":"Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif","volume":"24","author":"Olweus","year":"2010","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2011-06-357939","article-title":"TCR-transgenic lymphocytes specific for HMMR\/Rhamm limit tumor outgrowth","volume":"119","author":"Frankenberger","year":"2012","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2014-07-587840","article-title":"Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b","volume":"125","author":"Heemskerk","year":"2015","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Rooney","year":"2005","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Magnani","year":"2009","journal-title":"Lancet Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Savoldo","year":"2011","journal-title":"N Engl J Med"},{"key":"35","first-page":"237","article-title":"CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells","volume":"76","author":"Meyerson","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"key":"36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4161\/onci.20592","article-title":"A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)","volume":"1","author":"Kranz","year":"2012","journal-title":"Oncoimmunology"},{"key":"37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","article-title":"Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors","volume":"37","author":"Falkenburg","year":"2009","journal-title":"Exp Hematol"},{"key":"38","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1073\/pnas.89.8.3429","article-title":"HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides","volume":"89","author":"Wiley","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"39","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1073\/pnas.111162298","article-title":"Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex","volume":"98","author":"Falkenburg","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/nm.3359","article-title":"High-throughput identification of antigen-specific TCRs by TCR gene capture","volume":"19","author":"Hombrink","year":"2013","journal-title":"Nat Med"},{"key":"41","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2003-06-2070","article-title":"New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population","volume":"103","author":"Falkenburg","year":"2004","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T05:29:36Z","timestamp":1657344576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":41,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["12247","27689397"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12247","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}